Apellis (NASDAQ: APLS) insider files to sell 368 shares under Rule 144

Rhea-AI Filing Summary

Apellis Pharmaceuticals insider plans small stock sale under Rule 144. A person associated with Apellis Pharmaceuticals plans to sell 368 shares of common stock through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of $8,152.56 and 126,525,218 shares outstanding.

The 368 shares were acquired on 02/10/2026 through restricted stock vesting from the issuer as compensation. In the past three months, Mark J. Delong has sold additional blocks of Apellis common stock, including 1,780 shares on 01/13/2026 and 3,371 shares on 01/22/2026, for disclosed gross proceeds.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	368	8152.56	126525218	02/11/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/10/2026	Restricted Stock Vesting	Issuer			368	02/10/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Mark J. Delong 100 Fifth Avenue Waltham MA 02451	Common	01/13/2026	1780	39493.22
Mark J. Delong 100 Fifth Avenue Waltham MA 02451	Common	01/20/2026	1334	26403.73
Mark J. Delong 100 Fifth Avenue Waltham MA 02451	Common	01/22/2026	3371	73371.17

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filing for Apellis Pharmaceuticals (APLS) disclose?

The filing discloses an insider’s intention to sell 368 Apellis common shares under Rule 144. The shares are to be sold on NASDAQ through Fidelity, with an aggregate market value of $8,152.56 and total shares outstanding of 126,525,218 at the time referenced.

How many Apellis (APLS) shares does the insider plan to sell in this notice?

The insider plans to sell 368 shares of Apellis common stock. These shares were recently acquired through restricted stock vesting on 02/10/2026 as compensation from the issuer, and the planned sale will occur on NASDAQ via Fidelity Brokerage Services LLC.

How were the Apellis (APLS) shares being sold under this Form 144 acquired?

The 368 Apellis common shares were acquired on 02/10/2026 through restricted stock vesting. The issuer granted the shares as compensation, meaning no cash purchase occurred. The filing records this compensation-based acquisition before the planned Rule 144 sale.

What recent Apellis (APLS) stock sales by Mark J. Delong are reported?

The document reports several recent sales by Mark J. Delong of Apellis common stock. These include 1,780 shares sold on 01/13/2026, 1,334 shares on 01/20/2026, and 3,371 shares on 01/22/2026, with each transaction showing specific gross proceeds in dollars.

On which exchange and through which broker will the Apellis (APLS) shares be sold?

The planned 368-share sale will occur on the NASDAQ stock market. The broker handling the transaction is Fidelity Brokerage Services LLC, located at 900 Salem Street, Smithfield, Rhode Island, as specified in the Form 144 securities information table.

How many Apellis (APLS) shares were outstanding when this Form 144 was prepared?

The filing cites 126,525,218 Apellis common shares outstanding. This figure provides context for the planned 368-share sale under Rule 144, showing the overall size of the company’s equity base relative to the transaction described in the notice.